Form 4: Kronos Bio Director's Stock Options Cancelled for No Consideration Following Concentra Biosciences Merger

A recent SEC Form 4 filing reveals that Kronos Bio, Inc. Director Roshawn A. Blunt's stock options were cancelled without consideration as part of the company's acquisition by Concentra Biosciences, LLC.

Summary

• Kronos Bio, Inc. (KRON) has been acquired by Concentra Biosciences, LLC, through its wholly-owned subsidiary Concentra Merger Sub IV, Inc.
• The merger involved a tender offer completed on June 18, 2025, where outstanding shares of Kronos Bio common stock were acquired for an offer price of $0.57 per share in cash, plus one non-transferable contractual contingent value right (CVR).
• Following the tender offer, Merger Sub merged with Kronos Bio, Inc., making Kronos Bio a wholly-owned subsidiary of Concentra Biosciences, LLC.
• As part of the merger, all outstanding stock options to purchase Kronos Bio shares became fully vested and exercisable immediately prior to the merger's effective time.
• Unexercised options were cancelled and converted into a right to receive cash (if the cash offer price exceeded the option's exercise price) and one CVR per underlying share.
• However, if an option's exercise price was equal to or greater than the cash offer price of $0.57 per share, the option was cancelled for no consideration.
• Director Roshawn A. Blunt disposed of 143,200 stock options across four tranches with exercise prices ranging from $0.95 to $17.1, all of which were higher than the $0.57 cash offer price.
• Consequently, all of Roshawn A. Blunt's reported options were cancelled for no consideration.

Sentiment

Score: 3

Explanation: The sentiment is negative for the reporting person's specific option holdings, as they were cancelled for no consideration. While the merger itself provided some value to common shareholders, the outcome for these options represents a significant loss.

Positives

• The merger provided common shareholders of Kronos Bio, Inc. with a cash payment of $0.57 per share and a contingent value right (CVR), offering potential future value.

Negatives

• Director Roshawn A. Blunt's 143,200 stock options, with exercise prices ranging from $0.95 to $17.1, were cancelled for no consideration because their exercise prices exceeded the $0.57 cash offer price per share, resulting in a complete loss of value for these options.

Risks

• The value of the Contingent Value Rights (CVRs) issued to common shareholders is uncertain and dependent on future events, introducing a speculative element to the merger consideration.

Future Outlook

Kronos Bio, Inc. has become a wholly-owned subsidiary of Concentra Biosciences, LLC, indicating a cessation of its independent public operations. The future value for former common shareholders is partially tied to the performance and terms of the Contingent Value Rights (CVRs).

Industry Context

This filing reflects a common trend of consolidation within the biotechnology and pharmaceutical sectors, where larger entities acquire smaller companies, often for their pipeline assets or strategic capabilities. Such acquisitions frequently involve complex financial instruments like contingent value rights to bridge valuation gaps or share future risks/rewards.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $0.57 cash per share and one CVR for their common stock.
• Option Holders (like Roshawn A. Blunt): Options with exercise prices above the cash offer were cancelled for no consideration, resulting in a loss of value.

Next Steps

• The merger has been completed, with Kronos Bio, Inc. now operating as a wholly-owned subsidiary of Concentra Biosciences, LLC.
• The future value for former common shareholders will depend on the realization of value from the Contingent Value Rights (CVRs).

Key Dates

Keywords

SEC Form 4, Insider Transaction, Stock Options, Merger, Acquisition, Tender Offer, Contingent Value Rights, Kronos Bio, Concentra Biosciences, Beneficial Ownership